Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids

Trial Profile

Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs ABX 464 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Abivax
  • Most Recent Events

    • 04 Sep 2018 According to an Abivax media release, complete data from this study will be present at the upcoming international scientific conferences. Also, will be submitted for publication in a leading medical scientific journal.
    • 04 Sep 2018 Status changed from active, no longer recruiting to completed, according to an Abivax media release.
    • 04 Sep 2018 Top-line results presented in an Abivax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top